Pramipexole to Enhance Social Connections

PHASE2RecruitingINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

May 13, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Anxiety DisordersAnxietyDepressionSocial Disconnection
Interventions
DRUG

Pramipexole Pill

The study drug, pramipexole, is an FDA-approved medication for the treatment of Parkinson's and restless leg syndrome. Pramipexole (Mirapex) tablets are taken orally, with or without food.

DRUG

Placebo Pill

Placebo will match the study drug in mode of administration, color, size, and taste.

Trial Locations (2)

10032

NOT_YET_RECRUITING

New York State Psychiatric Institute, New York

92093

RECRUITING

University of California, San Diego, San Diego

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

collaborator

New York State Psychiatric Institute

OTHER

lead

University of California, San Diego

OTHER